Share Price and Basic Stock Data
Last Updated: November 28, 2025, 9:33 am
| PEG Ratio | 9.42 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sumitomo Chemical India Ltd operates in the agrochemicals and pesticides sector, a critical component of India’s agricultural economy. The company’s stock price stood at ₹455, with a market capitalization of ₹22,719 Cr. Over the years, Sumitomo has shown a robust revenue trajectory, recording sales of ₹3,511 Cr for the fiscal year ending March 2023, which marked a significant increase from ₹3,060 Cr in FY 2022. However, in FY 2024, sales declined to ₹2,833 Cr, reflecting challenges in the market. The trailing twelve months (TTM) sales were reported at ₹3,250 Cr, indicating a recovery trend as operations normalize. Quarterly sales figures also reveal fluctuations; for instance, the sales for June 2023 were ₹724 Cr, while September 2023 saw an increase to ₹903 Cr, suggesting seasonal variations in demand. These trends highlight both the resilience and volatility inherent in the agrochemical sector, influenced by factors such as weather conditions and regulatory changes.
Profitability and Efficiency Metrics
Sumitomo Chemical India has demonstrated solid profitability metrics, with a reported net profit of ₹540 Cr, translating to a return on equity (ROE) of 18.8% and a return on capital employed (ROCE) of 25.1%. The operating profit margin (OPM) stood at 21%, showcasing efficient cost management relative to industry averages. However, the company’s profitability faced challenges in recent quarters, with the OPM fluctuating; for example, it dipped to 11% in June 2023 but rebounded to 21% in March 2024. The net profit for the March 2025 fiscal year is set to reach ₹502 Cr, reflecting ongoing operational improvements. The interest coverage ratio (ICR) is noteworthy at 128.35x, indicating a strong ability to meet interest obligations, which is significantly higher than typical sector norms. This financial strength underscores the company’s operational efficiency, although ongoing volatility in margins poses a risk to sustained profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Sumitomo Chemical India reflects a solid foundation, with total assets reported at ₹3,930 Cr and a minimal debt level of ₹49 Cr, signifying a low leverage position. The company’s reserves reached ₹2,695 Cr, enhancing its financial stability. The current ratio stood at 3.13, indicating a strong liquidity position well above the typical industry benchmark, which generally hovers around 1.5 to 2. This robust liquidity allows the company to manage short-term obligations effectively. The price-to-book value (P/BV) ratio is 9.61x, indicating a premium valuation compared to many peers in the agrochemical sector. Furthermore, the dividend payout ratio remained at 8.88%, reflecting a balanced approach to returning capital to shareholders while retaining sufficient earnings for growth. Overall, the financial ratios suggest that Sumitomo is well-positioned to navigate industry challenges, although the high P/BV ratio may indicate market expectations that could be difficult to meet.
Shareholding Pattern and Investor Confidence
Investor confidence in Sumitomo Chemical India is evidenced by its shareholding pattern, where promoters hold a significant 75% stake, ensuring strong control over company operations. Foreign institutional investors (FIIs) hold 3.65%, while domestic institutional investors (DIIs) account for 8.47%. The public shareholding has gradually decreased to 12.88%, reflecting a consolidation of ownership, which may indicate confidence from institutional investors in the company’s long-term prospects. The number of shareholders stood at 1,15,793, down from higher figures in previous periods, which may suggest a shift towards larger institutional investment as retail participation wanes. The consistent promoter holding coupled with increasing institutional investments could be a positive signal for future growth, although the declining public shareholding might raise concerns about broader market engagement. This pattern indicates a trust in the company’s strategic direction, yet also highlights the need for improved communication with retail investors.
Outlook, Risks, and Final Insight
Looking ahead, the outlook for Sumitomo Chemical India appears cautiously optimistic, driven by its strong balance sheet and operational efficiencies. However, risks remain, particularly concerning fluctuating raw material prices and potential regulatory changes affecting the agrochemical sector. The company’s ability to maintain profitability amidst these challenges will be critical. If the company can leverage its financial strength to adapt to market conditions, it may achieve sustainable growth. Conversely, failure to manage costs effectively or to respond to regulatory pressures could impact its financial performance. In scenarios where market conditions stabilize, and demand for agrochemicals rises, Sumitomo could witness a significant rebound in revenues. However, persistent volatility in agricultural markets and environmental regulations could pose substantial risks to its growth trajectory. Overall, while the company has demonstrated resilience, ongoing vigilance will be essential to navigate the complexities of the agrochemical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Sumitomo Chemical India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 6,451 Cr. | 1,495 | 2,196/1,398 | 16.0 | 487 | 0.40 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 828 Cr. | 245 | 391/165 | 17.0 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 64.6 Cr. | 124 | 149/56.6 | 11.6 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,209 Cr. | 248 | 365/228 | 121 | 54.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 916 Cr. | 387 | 670/244 | 71.5 | 342 | 0.76 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,228.70 Cr | 1,496.67 | 33.19 | 472.46 | 0.43% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 986 | 1,122 | 753 | 652 | 724 | 903 | 540 | 664 | 832 | 971 | 622 | 665 | 1,048 |
| Expenses | 798 | 843 | 632 | 571 | 643 | 715 | 474 | 526 | 670 | 729 | 521 | 548 | 828 |
| Operating Profit | 188 | 278 | 121 | 81 | 81 | 188 | 66 | 139 | 162 | 242 | 101 | 117 | 220 |
| OPM % | 19% | 25% | 16% | 12% | 11% | 21% | 12% | 21% | 19% | 25% | 16% | 18% | 21% |
| Other Income | 5 | 11 | 13 | 17 | 18 | 25 | 27 | 27 | 26 | 31 | 31 | 31 | 39 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 11 | 15 | 11 | 14 | 14 | 16 | 16 | 16 | 14 | 15 | 18 | 16 | 15 |
| Profit before tax | 180 | 272 | 121 | 82 | 83 | 196 | 76 | 149 | 173 | 257 | 113 | 132 | 242 |
| Tax % | 23% | 26% | 25% | 12% | 26% | 27% | 27% | 26% | 26% | 26% | 25% | 25% | 26% |
| Net Profit | 138 | 202 | 91 | 72 | 62 | 144 | 55 | 109 | 128 | 191 | 84 | 98 | 180 |
| EPS in Rs | 2.77 | 4.05 | 1.82 | 1.45 | 1.24 | 2.88 | 1.10 | 2.19 | 2.57 | 3.82 | 1.69 | 1.97 | 3.60 |
Last Updated: August 20, 2025, 3:00 am
Below is a detailed analysis of the quarterly data for Sumitomo Chemical India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,048.00 Cr.. The value appears strong and on an upward trend. It has increased from 665.00 Cr. (Mar 2025) to 1,048.00 Cr., marking an increase of 383.00 Cr..
- For Expenses, as of Jun 2025, the value is 828.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 548.00 Cr. (Mar 2025) to 828.00 Cr., marking an increase of 280.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 220.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Mar 2025) to 220.00 Cr., marking an increase of 103.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 8.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 242.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 242.00 Cr., marking an increase of 110.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 180.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Mar 2025) to 180.00 Cr., marking an increase of 82.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.60. The value appears strong and on an upward trend. It has increased from 1.97 (Mar 2025) to 3.60, marking an increase of 1.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 635 | 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | 3,250 |
| Expenses | 587 | 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,467 | 2,595 |
| Operating Profit | 48 | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 | 655 |
| OPM % | 8% | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 20% |
| Other Income | 3 | 8 | 26 | 10 | 31 | -0 | -20 | 19 | 36 | 45 | 96 | 119 | 140 |
| Interest | 2 | 1 | 1 | 1 | 5 | 5 | 7 | 7 | 8 | 6 | 5 | 6 | 6 |
| Depreciation | 6 | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 | 65 |
| Profit before tax | 43 | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 | 724 |
| Tax % | 23% | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% | |
| Net Profit | 33 | 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | 540 |
| EPS in Rs | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | 10.82 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.06% | 85.71% | -4.62% | 133.87% | 15.17% | 23.35% | 67.48% | 25.80% | 15.90% | -26.44% | 35.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 79.65% | -90.33% | 138.49% | -118.70% | 8.18% | 44.12% | -41.68% | -9.90% | -42.34% | 62.12% |
Sumitomo Chemical India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 5% |
| 3 Years: | 0% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 17% |
| 3 Years: | 5% |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 6% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:36 pm
Balance Sheet
Last Updated: November 9, 2025, 3:01 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | -36 | -2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 | 2,695 |
| Borrowings | 0 | 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 | 49 |
| Other Liabilities | 243 | 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 | 1,158 |
| Total Liabilities | 440 | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,401 |
| Fixed Assets | 47 | 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 482 | 487 |
| CWIP | 0 | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 | 14 |
| Investments | 0 | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 | 1,292 |
| Other Assets | 393 | 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 | 2,608 |
| Total Assets | 440 | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,401 |
Below is a detailed analysis of the balance sheet data for Sumitomo Chemical India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 499.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 499.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,695.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,397.00 Cr. (Mar 2025) to 2,695.00 Cr., marking an increase of 298.00 Cr..
- For Borrowings, as of Sep 2025, the value is 49.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 45.00 Cr. (Mar 2025) to 49.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,158.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 988.00 Cr. (Mar 2025) to 1,158.00 Cr., marking an increase of 170.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,401.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,930.00 Cr. (Mar 2025) to 4,401.00 Cr., marking an increase of 471.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 487.00 Cr.. The value appears strong and on an upward trend. It has increased from 482.00 Cr. (Mar 2025) to 487.00 Cr., marking an increase of 5.00 Cr..
- For CWIP, as of Sep 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
- For Investments, as of Sep 2025, the value is 1,292.00 Cr.. The value appears strong and on an upward trend. It has increased from 601.00 Cr. (Mar 2025) to 1,292.00 Cr., marking an increase of 691.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,608.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,819.00 Cr. (Mar 2025) to 2,608.00 Cr., marking a decrease of 211.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,401.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,930.00 Cr. (Mar 2025) to 4,401.00 Cr., marking an increase of 471.00 Cr..
Notably, the Reserves (2,695.00 Cr.) exceed the Borrowings (49.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 48.00 | 57.00 | 89.00 | 101.00 | 209.00 | 271.00 | 299.00 | 455.00 | 565.00 | 634.00 | 449.00 | 578.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 |
| Inventory Days | 125 | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 154 |
| Days Payable | 134 | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 107 |
| Cash Conversion Cycle | 81 | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 136 |
| Working Capital Days | 58 | 69 | 79 | 113 | 113 | 116 | 109 | 95 | 127 | 136 | 173 | 183 |
| ROCE % | 25% | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| 360 ONE Focused Equity Fund | 3,623,637 | 2.38 | 146.41 | 3,623,637 | 2025-04-22 17:25:20 | 0% |
| Axis Midcap Fund | 2,222,646 | 0.37 | 89.81 | 2,222,646 | 2025-04-22 17:25:20 | 0% |
| HSBC Small Cap Fund - Regular Plan | 2,106,600 | 0.64 | 85.12 | 2,106,600 | 2025-04-22 17:25:20 | 0% |
| Axis Growth Opportunities Fund | 1,859,682 | 0.7 | 75.14 | 1,859,682 | 2025-04-22 17:25:20 | 0% |
| PGIM India Midcap Opportunities Fund | 1,578,298 | 0.63 | 63.77 | 1,578,298 | 2025-04-22 17:25:20 | 0% |
| ICICI Prudential MidCap Fund | 1,063,453 | 0.84 | 42.97 | 1,063,453 | 2025-04-22 17:25:20 | 0% |
| Tata Ethical Fund - Regular Plan | 797,200 | 1.47 | 32.21 | 797,200 | 2025-04-22 17:25:20 | 0% |
| Aditya Birla Sun Life MNC Fund - Div | 647,284 | 0.73 | 26.15 | 647,284 | 2025-04-22 17:25:20 | 0% |
| Aditya Birla Sun Life MNC Fund - Gr | 647,284 | 0.73 | 26.15 | 647,284 | 2025-04-22 17:25:20 | 0% |
| ICICI Prudential Manufacturing Fund | 508,258 | 0.9 | 20.54 | 508,258 | 2025-04-22 17:25:20 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.13 | 7.40 | 10.06 | 8.49 | 6.92 |
| Diluted EPS (Rs.) | 10.13 | 7.40 | 10.06 | 8.49 | 6.92 |
| Cash EPS (Rs.) | 11.47 | 8.65 | 11.10 | 9.38 | 7.85 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 58.12 | 48.97 | 47.72 | 38.61 | 30.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 58.12 | 48.97 | 47.72 | 38.61 | 30.88 |
| Revenue From Operations / Share (Rs.) | 63.08 | 56.98 | 70.34 | 61.40 | 52.99 |
| PBDIT / Share (Rs.) | 15.07 | 11.42 | 14.25 | 12.56 | 10.13 |
| PBIT / Share (Rs.) | 13.74 | 10.18 | 13.21 | 11.66 | 9.19 |
| PBT / Share (Rs.) | 13.63 | 10.08 | 13.11 | 11.53 | 9.08 |
| Net Profit / Share (Rs.) | 10.15 | 7.41 | 10.06 | 8.48 | 6.92 |
| NP After MI And SOA / Share (Rs.) | 10.13 | 7.40 | 10.06 | 8.48 | 6.92 |
| PBDIT Margin (%) | 23.88 | 20.05 | 20.26 | 20.45 | 19.10 |
| PBIT Margin (%) | 21.79 | 17.86 | 18.78 | 18.98 | 17.34 |
| PBT Margin (%) | 21.60 | 17.68 | 18.63 | 18.78 | 17.13 |
| Net Profit Margin (%) | 16.08 | 13.00 | 14.30 | 13.82 | 13.05 |
| NP After MI And SOA Margin (%) | 16.05 | 12.99 | 14.30 | 13.82 | 13.05 |
| Return on Networth / Equity (%) | 17.42 | 15.13 | 21.08 | 21.97 | 22.40 |
| Return on Capital Employeed (%) | 22.87 | 20.22 | 27.07 | 29.26 | 28.84 |
| Return On Assets (%) | 12.75 | 11.15 | 14.90 | 14.07 | 12.93 |
| Asset Turnover Ratio (%) | 0.86 | 0.85 | 1.10 | 1.08 | 1.11 |
| Current Ratio (X) | 3.13 | 3.34 | 2.99 | 2.47 | 2.14 |
| Quick Ratio (X) | 2.40 | 2.58 | 2.03 | 1.55 | 1.44 |
| Inventory Turnover Ratio (X) | 2.42 | 1.88 | 2.03 | 2.18 | 2.33 |
| Dividend Payout Ratio (NP) (%) | 8.88 | 83.74 | 9.93 | 9.42 | 7.95 |
| Dividend Payout Ratio (CP) (%) | 7.85 | 71.68 | 9.00 | 8.52 | 7.00 |
| Earning Retention Ratio (%) | 91.12 | 16.26 | 90.07 | 90.58 | 92.05 |
| Cash Earning Retention Ratio (%) | 92.15 | 28.32 | 91.00 | 91.48 | 93.00 |
| Interest Coverage Ratio (X) | 128.35 | 111.66 | 131.90 | 101.62 | 90.99 |
| Interest Coverage Ratio (Post Tax) (X) | 87.42 | 73.40 | 94.11 | 69.68 | 63.18 |
| Enterprise Value (Cr.) | 27850.93 | 17160.49 | 20923.34 | 22359.99 | 14273.20 |
| EV / Net Operating Revenue (X) | 8.85 | 6.03 | 5.96 | 7.30 | 5.40 |
| EV / EBITDA (X) | 37.03 | 30.09 | 29.41 | 35.68 | 28.24 |
| MarketCap / Net Operating Revenue (X) | 8.86 | 6.10 | 6.05 | 7.32 | 5.49 |
| Retention Ratios (%) | 91.11 | 16.25 | 90.06 | 90.57 | 92.04 |
| Price / BV (X) | 9.61 | 7.10 | 8.91 | 11.64 | 9.42 |
| Price / Net Operating Revenue (X) | 8.86 | 6.10 | 6.05 | 7.32 | 5.49 |
| EarningsYield | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 |
After reviewing the key financial ratios for Sumitomo Chemical India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 7.40 (Mar 24) to 10.13, marking an increase of 2.73.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 7.40 (Mar 24) to 10.13, marking an increase of 2.73.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.47. This value is within the healthy range. It has increased from 8.65 (Mar 24) to 11.47, marking an increase of 2.82.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 58.12. It has increased from 48.97 (Mar 24) to 58.12, marking an increase of 9.15.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 58.12. It has increased from 48.97 (Mar 24) to 58.12, marking an increase of 9.15.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 63.08. It has increased from 56.98 (Mar 24) to 63.08, marking an increase of 6.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.07. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 15.07, marking an increase of 3.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.74. This value is within the healthy range. It has increased from 10.18 (Mar 24) to 13.74, marking an increase of 3.56.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 10.08 (Mar 24) to 13.63, marking an increase of 3.55.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.15. This value is within the healthy range. It has increased from 7.41 (Mar 24) to 10.15, marking an increase of 2.74.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 7.40 (Mar 24) to 10.13, marking an increase of 2.73.
- For PBDIT Margin (%), as of Mar 25, the value is 23.88. This value is within the healthy range. It has increased from 20.05 (Mar 24) to 23.88, marking an increase of 3.83.
- For PBIT Margin (%), as of Mar 25, the value is 21.79. This value exceeds the healthy maximum of 20. It has increased from 17.86 (Mar 24) to 21.79, marking an increase of 3.93.
- For PBT Margin (%), as of Mar 25, the value is 21.60. This value is within the healthy range. It has increased from 17.68 (Mar 24) to 21.60, marking an increase of 3.92.
- For Net Profit Margin (%), as of Mar 25, the value is 16.08. This value exceeds the healthy maximum of 10. It has increased from 13.00 (Mar 24) to 16.08, marking an increase of 3.08.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.05. This value is within the healthy range. It has increased from 12.99 (Mar 24) to 16.05, marking an increase of 3.06.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.42. This value is within the healthy range. It has increased from 15.13 (Mar 24) to 17.42, marking an increase of 2.29.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.87. This value is within the healthy range. It has increased from 20.22 (Mar 24) to 22.87, marking an increase of 2.65.
- For Return On Assets (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has increased from 11.15 (Mar 24) to 12.75, marking an increase of 1.60.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.86. It has increased from 0.85 (Mar 24) to 0.86, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.13. This value exceeds the healthy maximum of 3. It has decreased from 3.34 (Mar 24) to 3.13, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 2.40. This value exceeds the healthy maximum of 2. It has decreased from 2.58 (Mar 24) to 2.40, marking a decrease of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.42. This value is below the healthy minimum of 4. It has increased from 1.88 (Mar 24) to 2.42, marking an increase of 0.54.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.88. This value is below the healthy minimum of 20. It has decreased from 83.74 (Mar 24) to 8.88, marking a decrease of 74.86.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 20. It has decreased from 71.68 (Mar 24) to 7.85, marking a decrease of 63.83.
- For Earning Retention Ratio (%), as of Mar 25, the value is 91.12. This value exceeds the healthy maximum of 70. It has increased from 16.26 (Mar 24) to 91.12, marking an increase of 74.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 92.15. This value exceeds the healthy maximum of 70. It has increased from 28.32 (Mar 24) to 92.15, marking an increase of 63.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 128.35. This value is within the healthy range. It has increased from 111.66 (Mar 24) to 128.35, marking an increase of 16.69.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 87.42. This value is within the healthy range. It has increased from 73.40 (Mar 24) to 87.42, marking an increase of 14.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 27,850.93. It has increased from 17,160.49 (Mar 24) to 27,850.93, marking an increase of 10,690.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.85. This value exceeds the healthy maximum of 3. It has increased from 6.03 (Mar 24) to 8.85, marking an increase of 2.82.
- For EV / EBITDA (X), as of Mar 25, the value is 37.03. This value exceeds the healthy maximum of 15. It has increased from 30.09 (Mar 24) to 37.03, marking an increase of 6.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 6.10 (Mar 24) to 8.86, marking an increase of 2.76.
- For Retention Ratios (%), as of Mar 25, the value is 91.11. This value exceeds the healthy maximum of 70. It has increased from 16.25 (Mar 24) to 91.11, marking an increase of 74.86.
- For Price / BV (X), as of Mar 25, the value is 9.61. This value exceeds the healthy maximum of 3. It has increased from 7.10 (Mar 24) to 9.61, marking an increase of 2.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 6.10 (Mar 24) to 8.86, marking an increase of 2.76.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sumitomo Chemical India Ltd:
- Net Profit Margin: 16.08%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.87% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.42% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 87.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 42.2 (Industry average Stock P/E: 33.19)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.08%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Bldg. No. 1, Ground Floor, Shant Manor Co-op Housing Society Ltd., Mumbai Maharashtra 400101 | investor.relations@sumichem.co.in http://www.sumichem.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mukul G Asher | Chairman |
| Mr. Chetan Shah | Managing Director |
| Dr. Suresh Ramachandran | Deputy Managing Director |
| Mr. Sushil Marfatia | Executive Director |
| Mr. N Sivaraman | Independent Director |
| Mrs. Preeti Mehta | Independent Director |
| Mr. Ninad D Gupte | Non Exe.Non Ind.Director |
| Mr. Masanori Uzawa | Non Exe.Non Ind.Director |
| Mr. Tadashi Katayama | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Sumitomo Chemical India Ltd?
Sumitomo Chemical India Ltd's intrinsic value (as of 28 November 2025) is 407.26 which is 10.88% lower the current market price of 457.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 22,789 Cr. market cap, FY2025-2026 high/low of 665/442, reserves of ₹2,695 Cr, and liabilities of 4,401 Cr.
What is the Market Cap of Sumitomo Chemical India Ltd?
The Market Cap of Sumitomo Chemical India Ltd is 22,789 Cr..
What is the current Stock Price of Sumitomo Chemical India Ltd as on 28 November 2025?
The current stock price of Sumitomo Chemical India Ltd as on 28 November 2025 is 457.
What is the High / Low of Sumitomo Chemical India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sumitomo Chemical India Ltd stocks is 665/442.
What is the Stock P/E of Sumitomo Chemical India Ltd?
The Stock P/E of Sumitomo Chemical India Ltd is 42.2.
What is the Book Value of Sumitomo Chemical India Ltd?
The Book Value of Sumitomo Chemical India Ltd is 64.0.
What is the Dividend Yield of Sumitomo Chemical India Ltd?
The Dividend Yield of Sumitomo Chemical India Ltd is 0.26 %.
What is the ROCE of Sumitomo Chemical India Ltd?
The ROCE of Sumitomo Chemical India Ltd is 25.1 %.
What is the ROE of Sumitomo Chemical India Ltd?
The ROE of Sumitomo Chemical India Ltd is 18.8 %.
What is the Face Value of Sumitomo Chemical India Ltd?
The Face Value of Sumitomo Chemical India Ltd is 10.0.